Genus Capital Management Inc. Sells 14,048 Shares of Insulet Corporation $PODD

Genus Capital Management Inc. cut its holdings in Insulet Corporation (NASDAQ:PODD) by 91.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,271 shares of the medical instruments supplier’s stock after selling 14,048 shares during the quarter. Genus Capital Management Inc.’s holdings in Insulet were worth $361,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter valued at $28,000. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of Insulet in the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Insulet in the second quarter valued at $51,000.

Analysts Set New Price Targets

PODD has been the subject of a number of research reports. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. TD Cowen lowered Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Oppenheimer lowered their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Barclays lowered their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Finally, Robert W. Baird lowered their target price on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $254.96.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.36% of the company’s stock.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $154.87 on Tuesday. The stock has a market capitalization of $10.73 billion, a P/E ratio of 36.02, a P/E/G ratio of 1.22 and a beta of 1.20. Insulet Corporation has a 1-year low of $145.59 and a 1-year high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $189.91 and a two-hundred day moving average price of $249.64.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts predict that Insulet Corporation will post 6.43 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.